Table 2 Adverse events with bupivacaine and levobupivacaine
A. Intraoperative adverse events | ||||||
|---|---|---|---|---|---|---|
Total (N =120) | BUPI (N =60) | LEVO (N =60) | ||||
N | % | N | % | N | % | |
Stroke | 1 | 1% | 0 | 0% | 1 | 2% |
Hypotension | 31 | 26% | 3 | 38%★ | 8 | 13% |
Vomiting | 1 | 1% | 1 | 2% | 0 | 0% |
RBC transfusion | 27 | 22% | 8 | 13% | 19 | 32%★ |
B. Adverse events at 48 hours after surgery | ||||||
Total (N =120) | BUPI (N =60) | LEVO (N =60) | ||||
N | % | N | % | |||
Pneumonia | 1 | 1% | 1 | 2% | 0 | 0% |
CHF | 5 | 4% | 5 | 8%★ | 0 | 0% |
RF | 4 | 3% | 2 | 3% | 2 | 3% |
RBC | ||||||
Transfusion | 34 | 28% | 16 | 26% | 18 | 30% |
C. Adverse events at 6 months postoperatively | ||||||
Total (N =120) | BUPI (N =60) | LEVO (N =60) | ||||
N | % | N | % | N | % | |
Exacerbation of kidney disease | 3 | 2% | 2 | 3 | 1 | 2% |
Death | 8 | 7% | 5 | 8% | 3 | 5% |
Exacerbation of cardio-vascular disease | 5 | 4% | 4 | 7% | 1 | 2% |
Exacerbation of pulmonary disease | 4 | 3% | 2 | 3% | 2 | 3% |